Lotus Pharmaceuticals
在场
Lotus Pharmaceuticals 的所有者是 Alvogen.
Alvogen 在 4 个国家有直接业务。
Alvogen 拥有 5家子公司，其中包括 Adalvo、Alvogen Americas 和 Alvogen APAC。
他们在：
高管
药店
Alvogen 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
Lotus Pharmaceuticals 的最新新闻稿
- Lotus marked historical high for 2023 revenues, profit and cash dividend - Lotus
- Lotus Reported Unaudited February Revenues of NT$1,052 Million - Lotus
- Lotus Reported Unaudited January Revenues of NT$1,996 Million, surging 45.4% MoM - Lotus
- Lotus Reported Unaudited December Consolidated Revenues of NT$1,372 million, showcasing MoM and YoY Growth 2023 Unaudited Consolidated Revenues Grew 16% to NT$16,958 million, marking 5th consecutive year of double-digit growth - Lotus
- Lotus and Favorex Pte Ltd Announces Strategic Partnership to Commercialize an Ustekinumab Biosimilar in South Korea - Lotus
- Lotus Pharmaceutical Announces First Shipment of Lenalidomide to Japan - Lotus
- Lotus Achieves Historic Q3 2023 Results with YTD EPS Soaring to a Record NTD 14.19 Marking a 29% Year-on-Year Growth - Lotus
- Lotus and Intas Announce Strategic Partnership to Commercialize Denosumab Biosimilar in Asia - Lotus
- Lotus Reported Unaudited November Consolidated Revenues of NT$1,135 million, representing 25% MoM Growth and 6% YoY Growth - Lotus
- Lotus Hosts Third Quarter 2023 Results Investor Conference - Lotus
- View more press releases Close
通过电子邮件
